Test Directory
| Test Code | ||||||||||||||||||||||||||||||
| 1463 | ||||||||||||||||||||||||||||||
| Test Name | ||||||||||||||||||||||||||||||
| Alport Syndrome, X-linked | ||||||||||||||||||||||||||||||
| CPT Codes | ||||||||||||||||||||||||||||||
| 81407, 81408 | ||||||||||||||||||||||||||||||
| Expected Turnaround Time | ||||||||||||||||||||||||||||||
| Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited. | ||||||||||||||||||||||||||||||
| Clinical Utility | ||||||||||||||||||||||||||||||
| Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members. | ||||||||||||||||||||||||||||||
| Specimen and Container Info | ||||||||||||||||||||||||||||||
|
Non-Prenatal Specimens
Prenatal Specimens Either specimen type below is acceptable.
NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico. |
||||||||||||||||||||||||||||||
| Transport Instructions | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Stability Requirements | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Causes for Rejection | ||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Methodology | ||||||||||||||||||||||||||||||
| Next Generation Sequencing and Copy Number Variation Analysis | ||||||||||||||||||||||||||||||
| Performing Location | ||||||||||||||||||||||||||||||
| Genomics - Snowdrift | ||||||||||||||||||||||||||||||
| Alternate Names | ||||||||||||||||||||||||||||||
| ATS | ||||||||||||||||||||||||||||||
| Description | ||||||||||||||||||||||||||||||
|
Alport syndrome is a genetically heterogeneous disorder with autosomal dominant, autosomal recessive and X-linked inheritance. The estimated prevalence is about 1 in 50,000 live births. All forms are caused by mutations in the genes encoding type IV collagen, which is a basement membrane component. Alport syndrome is characterized by a progressive glomerulonephropathy, sensorineural hearing loss and various ocular anomalies. The X-linked form (ATS; MIM 301050) represents about 85% of Alport syndrome cases and is caused by mutations in the COL4A5 gene. COL4A5 encodes the collagen %u03B15 (IV) chain. Most affected males demonstrate macro / microscopic hematuria at an early age and almost all of them develop end stage renal failure later in life. Female carriers may have intermittent hematuria and 30-40% of them have a life-long risk to develop end stage renal disease. High-tone sensorineural hearing loss is estimated to affect 80-90% of males by age of 40 years whereas it is less frequent in females with ATS and tends to occur later in life. Ocular abnormalities are also common and consist of anterior lenticonus, which is virtually pathognomonic for Alport syndrome, cataracts, pigmentary retinal changes (dot and fleck retinopathy) and corneal erosions. Penetrance in X-linked Alport syndrome is estimated to be 0.85 in females and 1.0 in males. |
||||||||||||||||||||||||||||||
| Testing Schedule | ||||||||||||||||||||||||||||||
| Monday-Friday | ||||||||||||||||||||||||||||||
| Genes | ||||||||||||||||||||||||||||||
| COL4A5 | ||||||||||||||||||||||||||||||
| MIM | ||||||||||||||||||||||||||||||
| 301050 | ||||||||||||||||||||||||||||||
| Disease Group | ||||||||||||||||||||||||||||||
| Hearing Disorders, Nephrology | ||||||||||||||||||||||||||||||
The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. View the Terms.
© 2026 HNL Lab Medicine. All rights reserved.